Back to Journals » International Journal of Nanomedicine » Volume 15

Development and in vitro Evaluation of Gastro-protective Aceclofenac-loaded Self-emulsifying Drug Delivery System

Authors Jianxian C, Saleem K, Ijaz M, Ur-Rehman M, Murtaza G, Asim MH

Received 17 February 2020

Accepted for publication 15 June 2020

Published 23 July 2020 Volume 2020:15 Pages 5217—5226


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Anderson Oliveira Lobo

Chen Jianxian,1,2 Kalsoom Saleem,3 Muhammad Ijaz,4 Masood Ur-Rehman,3 Ghulam Murtaza,4 Mulazim Hussain Asim5

1School of Economics, Capital University of Economics and Business, Beijing, People’s Republic of China; 2Chapter of traditional Chinese Medicine, China Information Industry Association, Beijing, China; 3Riphah Institute of Pharmaceutical Sciences, Islamabad, Pakistan; 4COMSATS University Islamabad, Lahore Campus, Lahore 54000, Pakistan; 5Institute of Pharmaceutical Technology, University of Innsbruck, Innsbruck 6020, Austria

Correspondence: Muhammad Ijaz
Lahore Campus, COMSATS University Islamabad, Lahore 54000, Pakistan
Tel +0092-42-99204787
Masood Ur-Rehman
Riphah Institute of Pharmaceutical Sciences, Islamabad, Pakistan

Aim: Chronic use of oral nonsteroidal anti-inflammatory drugs (NSAIDs) is commonly associated with gastric irritation and gastric ulceration. Therefore, the aim of study was to develop a novel oral drug delivery system with minimum gastric effects and improved dissolution rate for aceclofenac (ACF), a model BCS class-II drug.
Methods: Self-emulsifying drug delivery systems (SEDDS) were formulated to increase the solubility and ultimately the oral bioavailability of ACF. Oleic acid was used as an oil phase, Tween 80 (T80) and Kolliphor EL (KEL) were used as surfactants, whereas, polyethylene glycol 400 (PEG 400) and propylene glycol (PG) were employed as co-surfactants. Optimized formulations (F1, F2, F3 and F4) were analyzed for droplet size, poly dispersity index (PDI), cell viability studies, in vitro dissolution in both simulated gastric fluid and simulated intestinal fluid, ex vivo permeation studies and thermodynamic stability.
Results: The optimized formulations showed mean droplet sizes in the range of 111.3 ± 3.2 nm and 470.9 ± 12.52 nm, PDI from 244.6 nm to 389.4 ± 6.51 and zeta-potential from − 33 ± 4.86 mV to − 38.5 ± 5.15 mV. Cell viability studies support the safety profile of all formulations for oral administration. The in vitro dissolution studies and ex vivo permeation analysis revealed significantly improved drug release ranging from 95.68 ± 0.02% to 98.15 ± 0.71% when compared with control. The thermodynamic stability studies confirmed that all formulations remain active and stable for a longer period.
Conclusion: In conclusion, development of oral SEDDS might be a promising tool to improve the dissolution of BCS class-II drugs along with significantly reduced exposure to gastric mucosa.

Keywords: self-emulsification, BCS class-II, solubility, gastric irritation, gastro-protective, nano-emulsion

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]